Fusion Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Fusion Pharmaceuticals

08/08/2023 13:30

* Fusion Pharmaceuticals Inc  FUSN.OQ  reported a quarterly
adjusted loss of 38 cents​​ per share for the quarter ended in
June. The mean expectation of nine analysts for the quarter was
for a loss of 39 cents per share.
    * Revenue fell 94% to $34.00 thousand from a year ago;
analysts
expected $84.38 thousand. 
    * Fusion Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 38 cents​.
    * The mean earnings estimate of analysts had risen by
about 18.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Fusion Pharmaceuticals Inc shares had fallen by 35.3% this
quarter and lost 4.1% so far this year.
    * The company reported a quarterly loss of $25.18 million.
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $12.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 12:30 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.39          -0.38          Beat
 Mar. 31 2023      -0.32          -0.45          Missed
 Dec. 31 2022      -0.56          -0.55          Beat
 Sep. 30 2022      -0.50          -0.55          Missed